ArticleBMJ digital health & AI2026
In vivo clinical effectiveness of artificial intelligence screening for acute coronary syndrome: testing real-world performance.
Article in BMJ digital health & AI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Objective: Many predictive models are being developed, but few are deployed in clinical care. Hence, model performance within live real-world care is often not known. We trained a predictive model (in vitro) to (1) estimate patients' risk of acute coronary syndrome (ACS) on arrival to the emergency department (ED) and (2) identify those with highest risk for ST-segment myocardial infarction (STEMI) to receive an early ECG. We embedded this model into clinical care as clinical decision support (CDS) and using dynamic real-world data (in vivo), ran a silent pilot. We aimed to test the CDS's replication of the original model's screening performance and compare to standard of care screening by human staff. Methods and analysis: The CDS prospectively assessed each patient arriving in the ED between November 2023 and April 2024. It calculated each patient's risk for ACS, recorded a decision about whether the patient should receive an early ECG and was programmed to not exceed the total number of ECGs performed in human practice, approximately 33%. We used raw agreement and Cohen's Kappa to compare the screening decisions of the in vivo CDS and original in vitro model. We then measured sensitivity for ACS, our primary outcome, and specificity, which we compared between the CDS's and human screening decisions. Results: 32 346 visits were seen in the ED and processed by the CDS. 1.0% had ACS and 0.1% STEMI. Raw agreement between the CDS and original model was 96.8%, and Kappa was 91.2% (95% CI 90.7% to 91.8%). Sensitivity for ACS was 81.7% (95% CI 77.1% to 85.8%) in CDS versus 80.2% (95% CI 75.4% to 84.4%) observed in humans. Specificity for ACS was 67.3% (95% CI 66.8% to 67.9%) versus 67.4% (95% CI 66.9 to 67.9%), respectively. Conclusion: We found very good raw agreement and Kappa scores between the CDS and original model. Sensitivity and specificity between the CDS and human practice did not differ. This suggests that, when CDS is deployed independent of human decision-making, we can expect very high, although not perfect, performance replication. These differences need to be quantified and considered to estimate the real-world impact of models before deployment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.